333 filings
Page 2 of 17
8-K
1c19uqi7vgh68ahh
2 Jan 24
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
4:00pm
8-K
809uug143 wgz7vgut2
18 Dec 23
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
4:15pm
8-A12B/A
2civ16 qewrd
18 Dec 23
Registration of securities on exchange (amended)
4:05pm
8-K
i50w1v3wx
18 Dec 23
Entry into a Material Definitive Agreement
4:01pm
8-K
6sla4 qdij9friqzu
29 Nov 23
Other Events
4:00pm
8-K
bkzd7mjj1sx pcn
27 Nov 23
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
4:00pm
8-K
cwsr y0b0
15 Nov 23
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
4:13pm
8-K
8noe66r8axzjca6lsh8
1 Nov 23
INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update
4:13pm
8-K
dwd2mefopdjyextq5j
31 Oct 23
Regulation FD Disclosure
4:25pm
8-K
xambzuwwfda2kaheevf
17 Oct 23
INmune Bio Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, November 1
7:03pm
8-K
umd orv0ulnvpv4
7 Sep 23
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
9:10am
8-K
qo4uc9e5owbwx
5 Sep 23
Other Events
4:00pm
8-K
bg6 g4uwu
16 Aug 23
Entry into a Material Definitive Agreement
4:41pm
424B5
q8q89
16 Aug 23
Prospectus supplement for primary offering
4:39pm
8-K
7vscchsap
8 Aug 23
INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update
4:01pm
8-K
7nhsu
2 Aug 23
INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference
6:02am
8-K
e8otkfmfzdiofn478
31 Jul 23
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
6:02pm
8-K
qo78jtm mer6ps
27 Jul 23
Other Events
4:43pm